Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 770

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 770
---
 upon
our ability to meet our financial requirements, raise additional capital, and achieve gross profitability from our single marketed product.
To achieve profitability, we expect we will need to raise additional capital to fund our activities relating to commercial support for
our existing product and any future clinical research trials and operating activities. However, there can be no assurance that we
will ever achieve or maintain profitability. These conditions, among others, raise substantial doubt about our ability to continue as
a going concern for one year from the date these financial statements are issued.

We plan to fund our operations through third party
and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such
a time as the business achieves profitability or a business combination may be achieved. However, there can be no assurance that we will
be successful in raising additional capital or that such capital, if available, will be on terms that are favorable to us. Debt financing
and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations,
or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams,
research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our
common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit,
reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates
even if we would otherwise prefer to develop and market such product candidates ourselves.

As such, we have concluded that such plans do
not alleviate the substantial doubt about our ability to continue as a going concern for one year from the date the accompanying financial
statements are issued.

The accompanying financial statements have been prepared on a going
concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business, and
do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to
continue as a going concern.

53

Contractual Obligations

The following table summarizes our contractual obligations as of December
31, 2024:

    Payments Due By Period 

    Total  
    Less than 
    1 year